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MUCOPOLYSACCHARIDOSIS (MPS) TYPE III
 Autosomal recessive 
 Lysosomal Storage Disorders
 Sub-type of MPSs;
glycosaminoglycans (GAGs)
 Accumulated substrate: heparan sulphate 
 4 different diseases:
 III A
 III B
 III C
 III D
depending on the defective enzyme
 Chronic
 Progressive
 Large spectrum of severity 
& symptoms
MPS III 
(= Sanfilippo Syndrome)
MUCOPOLYSACCHARIDOSES (MPS)
AVAILABLE THERAPIES
 None!
…only symptomatic!
ameliorate symptoms
support disabled patients
ERT for neurodegenerative MPS would require the
introduction of active enzyme into the CNS

extra difficulties!
Still, it’s being attempted with
some promissing results
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Perfect Target 
for
Substrate Reduction
Approaches! 
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gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
siRNA
MPS III fibroblasts 
siRNAs
RISC
Control fibroblasts 
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
siRNA
24/48h incubation
harvest cells
RNA extraction
cDNA synthesis
qRT-PCR (target gene expression assessment)  
Livak method
NT
mRNA
MPS III A MPS III C MPS III D
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
siRNA
MPS III fibroblasts 
GAGs
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
siRNA
MPS III fibroblasts 
GAGs
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
siRNA
MPS III fibroblasts 
Further validation: 
  nr of experiments;
 immunocytochemistry
(anti-HS antibody)
 + tests in MPS IIIB
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siRNA
MPS III fibroblasts 
Promising results!
Reasons to keep studying...
A LOOK FORWARD…
 Vector design & siRNA encapsulation into liposomes
  bioavailability of siRNAs;
 protection from degradation
 control of 
 circulation time
 release rate 
 Coupling of specific ligands to 
siRNA-carrying liposomes
o Transferrin (Tf)
o Rabies virus peptide derivative (RGV-2r)
 Efficiency assessment
+ Targeting of brain cells
A LOOK FORWARD…
in vivo 
studies
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“early stages”  GAGs
biosynthesis gene
 GAG storage
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Therapeutic use 
SUMMARY
gSRT FOR MUCOPOLYSACCHARIDOSIS TYPE III
“early stages”  GAGs
biosynthesis gene
Holds potential to benefit 
virtually all MPS!
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